Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2025)

Сердечно-сосудистые заболевания являются одной из основных причин смертности и инвалидизации среди населения стран-участниц Евразийской Ассоциации кардиологов, что напрямую связано с высокой распространенностью факторов риска атеросклероза, среди которых ведущую роль играют дислипидемии. Предыдущая версия Евразийских рекомендаций по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза была представлена в 2020 году. За истекшие 5 лет существенно изменились подходы к стратификации риска, диагностике субклинического атеросклероза, коррекции дислипидемии с помощью различных классов гиполипидемических препаратов. Из приницпиальных обновлений следует выделить предложения по определению уровня липидов крови у каждого взрослого человека или по достижении 18 лет, использования шкал SCORE и/или SCORE2 для стратификации сердечно-сосудистого риска, неинвазивных визуализационных методик для оценки субклинического атеросклероза. В разделах, посвященных терапии, представлены фиксированные комбинации гиполипидемических препаратов, инклисиран, бемпедоевая кислота. Расширены раздел, посвященный распространенности, значимости и подходам к коррекции гипертриглицеридемии, а также раздел по экстракорпоральной гемокоррекции. Введена глава, посвященная липопротеиду(а). Представлены разделы, посвященные коррекции дислипидемии при цереброваскулярных болезнях, трансплантации сердца и ВИЧ-инфекции. Данные рекомендации будут полезны врачам всех специальностей для эффективного ведения своих пациентов.

1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. https:// doi.org/10.1093/eurheartj/ehz455

2. Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH, Almahmeed W, Alonso R, Daccord M, Ezhov M, Olmo RF, Jankowski P, Lanas F, Mehta R, Puri R, Wong ND, Wood D, Zhao D, Gidding SS, Virani SS, Lloyd-Jones D, Pinto F, Perel P, Santos RD. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022 Oct 14;17(1):75. https://doi.org/10.5334/gh.1154

3. Langsted A., Nordestgaard B.G. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019;51(2):131-141. https://doi.org/10.1016/j.pathol.2018.09.062

4. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454. https://doi.org/10.1093/eurheartj/ehab309

5. Балахонова Т. В., Ершова А. И., Ежов М. В., Барбараш О. Л., Берштейн Л. Л., Богачев В. Ю., Воевода М. И., Генкель В. В., Гуревич В. С., Дупляков Д. В., Имаев Т. Э., Коновалов Г. А., Космачева Е. Д., Лобастов К. В., Митькова М. Д., Никифоров В. С., Ротарь О. П., Сучков И. А., Явелов И. С., Митьков В. В., Акчурин Р. С., Драпкина О. М., Бойцов С. А. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):105-126. https://doi.org/10.15829/1728-8800-2022-3333 [Balakhonova T.V., Ershova A.I., Ezhov M.V., Barbarash O.L., Bershtein L.L., Bogachev V.Yu., Voevoda M.I., Genkel V.V., Gurevich V.S., Duplyakov D.V., Imaev T.E., Konovalov G.A., Kosmacheva E.D., Lobastov K.V., Mitkova M.D., Nikiforov V.S., Rotar O.P., Suchkov I.A., Yavelov I.S., Mitkov V.V., Akchurin R.S., Drapkina O.M., Boytsov S.A. Focused vascular ultrasound. Consensus of Russian experts. Cardiovascular Therapy and Prevention. 2022;21(7):105-126 (In Russ.) https://doi.org/10.15829/1728-8800-2022-3333]

6. Haq A, Veerati T, Walser-Kuntz E, Aldujeli A, Tang M, Miedema M. Coronary artery calcium and the risk of cardiovascular events and mortality in younger adults: a meta-analysis. Eur J Prev Cardiol. 2024 Jul 23;31(9):1061-1069. https://doi.org/10.1093/eurjpc/zwad399

7. Mortensen M.B., Falk E., Li D., et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2018;11(2):221-230. https://doi.org/10.1016/j.jcmg.2017.01.029

8. Meijboom W.B., Meijs M.F., Schuijf J.D., et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008;52(25):2135-2144. https://doi.org/10.1016/j.jacc.2008.08.058

9. Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men andwomen: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397-405. https://doi.org/10.1016/S0140-6736(14)61368-4

10. McDermott M.M., Kramer C.M., Tian L., et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. JACC: Cardiovascular Imaging. 2017;10(9):1003-1012. https://doi.org/10.1016/j.jcmg.2016.08.012

11. Sillesen H., Sartori S., Sandholt B., et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. European Heart Journal – Cardiovascular Imaging. 2017;19(9):1042-1050. https://doi.org/10.1093/ehjci/jex239

12. Fuster V, García-Álvarez A, Devesa A, Mass V, Owen R, Quesada A, Fuster JJ, García-Lunar I, Pocock S, Sánchez-González J, Sartori S, Peyra C, Andres V, Muntendam P, Ibanez B. Influence of Subclinical Atherosclerosis Burden and Progression on Mortality. J Am Coll Cardiol. 2024 Oct 8;84(15):1391-1403. https://doi.org/10.1016/j.jacc.2024.06.045

13. Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. https://doi.org/10.1056/NEJMoa1800389

14. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group; Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008 Jun 15;101(12):1689-93. https://doi.org/10.1016/j.amjcard.2008.02.056

15. Trogkanis E, Karalexi MA, Sergentanis TN, Kornarou E, Vassilakou T. Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis. Nutrients. 2024 May 11;16(10):1453. https://doi.org/10.3390/nu16101453

16. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. https://doi.org/10.1161/CIR.0000000000001168

17. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. https://doi.org/10.1093/eurheartj/ehac361

18. US Preventive Services Task Force; Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Stevermer J, Wong JB. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Aug 23;328(8):746-753. https://doi.org/10.1001/jama.2022.13044

19. Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019 Jan;20(1):103-113. https://doi.org/10.1080/14656566.2018.1544243

20. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-2397. https://doi.org/10.1056/NEJMoa1410489

21. Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75):A Randomized, Controlled Trial. Circulation. 2019 Sep 17;140(12):992-1003. https://doi.org/10.1161/CIRCULATIONAHA.118.039415

22. Farnier M, Santos RD, Cosin-Sales J, Ezhov MV, Liu J, Granados D, Santoni S, Khan I, Catapano AL. Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries. Eur J Prev Cardiol. 2022 Dec 7;29(17):2264-2271. https://doi.org/10.1093/eurjpc/zwac214

23. Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacology and Toxicology. 2014. 54(1):273-293. https://doi.org/10.1146/annurev-pharmtox-011613-140025

24. Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713-1722. https://doi.org/10.1056/nejmoa1615664

25. Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. https://doi.org/10.1056/NEJMoa1801174

26. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 Mar 19;139(12):1483-1492. https://doi.org/10.1161/CIRCULATIONAHA.118.037184

27. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Committees and Investigators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. https://doi.org/10.1016/j.jacc.2019.10.057

28. Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, Talloczy Z, Zang X, Maheux P, Lesogor A, Landmesser U. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3):results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. https://doi.org/10.1016/S2213-8587(22)00353-9

29. Cicero AFG, Fogacci F, Cincione I. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1031-1038. https://doi.org/10.1080/17425255.2021.1951222

30. Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ESG, Robinson P, Lei L, Ray KK. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022 Jul 1;174:1-11. https://doi.org/10.1016/j.amjcard.2022.03.020

31. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023 Apr 13;388(15):1353-1364. https://doi.org/10.1056/NEJMoa2215024

32. Драпкина О.М., Имаева А.Э., Куценко В.А., Капустина А.В., Баланова Ю.А., Максимов С.А., Муромцева Г.А., Котова М.Б., Карамнова Н.С., Евстифеева С.Е., Литинская О.А., Покровская М.С., Имаева Н.А., Филичкина Е.М., Ивлев О.Е., Свинин Г.Е., Гоманова Л.И., Долудин Ю.В., Ефимова И.А., Борисова А.Л., Назаров Б.М., Яровая Е.Б., Репкина Т.В., Гоношилова Т.О., Кудрявцев А.В., Белова Н.И., Шагров Л.Л., Самотруева М.А., Ясенявская А.Л., Чернышева Е.Н., Глуховская С.В., Левина И.А., Ширшова Е.А., Доржиева Е.Б., Урбанова И.З., Боровкова Н.Ю., Курашин В.К., Токарева А.С., Рагино Ю.И., Симонова Г.И., Шрамко В.С., Никулин В.Н., Аслямов О.Р., Хохлова Г.В., Соловьева А.В., Родионов А.А., Крячкова О.В., Шамурова Ю.Ю., Танцырева И.В., Барышникова И.Н., Атаев М.Г., Раджабов М.О., Исаханова М.М., Уметов М.А., Эльгарова Л.В., Хакуашева И.А., Ямашкина Е.И., Есина М.В., Куняева Т.А., Никитина А.М., Саввина Н.В., Спиридонова Ю.Е., Наумова Е.А., Кескинов А.А., Юдин В.С., Юдин С.М., Концевая А.В., Шальнова С.А. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3791. EDN DGYJLA. https://doi.org/10.15829/1728-8800-2023-3791 [Drapkina O.M., Imaeva A.E., Kutsenko V.A., Kapustina A.V., Balanova Yu.A., Maksimov S.A., Muromtseva G.A., Kotova M.B., Karamnova N.S., Evstifeeva S.E., Litinskaya O.A., Pokrovskaya M.S., Imaeva N.A., Filichkina E.M., Ivlev O.E., Svinin G.E., Gomanova L.I., Doludin Yu.V., Efimova I.A., Borisova A.L., Nazarov B.M., Yarovaya E.B., Repkina T.V., Gonoshilova T.O., Kudryavtsev A.V., Belova N.I., Shagrov L.L., Samotrueva M.A., Yasenyavskaya A.L., Chernysheva E.N., Glukhovskaya S.V., Levina I.A., Shirshova E.A., Dorzhieva E.B., Urbanova E.Z., Borovkova N.Yu., Kurashin V.K., Tokareva A.S., Ragino Yu.I., Simonova G.I., Shramko V.S., Nikulin V.N., Aslyamov O.R., Khokhlova G.V., Solovyova A.V., Rodionov A.A., Kryachkova O.V., Shamurova Yu.Yu., Tantsyreva I.V., Baryshnikova I.N., Ataev M.G., Radjabov M.O., Isakhanova M.M., Umetov M.A., Elgarova L.V., Khakuasheva I.A., Yamashkina E.I., Esina M.V., Kunyaeva T.A., Nikitina A.M., Savvina N.V., Spiridonova Yu.E., Naumova E.A., Keskinov A.A., Yudin V.S., Yudin S.M., Kontsevaya A.V., Shalnova S.A. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791. (In Russ.). EDN: DGYJLA. https:// doi.org/10.15829/1728-8800-2023-3791]

33. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, Watts GF, Wiklund O; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66. Epub 2013 Dec 23. PMID: 24731657; PMCID: PMC4201123. https://doi.org/10.1016/S2213-8587(13)70191-8

34. Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, Ladden-Stirling AB, Miller M, Orringer CE, Stone NJ. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Aug 31;78(9):960-993. https://doi.org/10.1016/j.jacc.2021.06.011

35. Arca M., Veronesi C., D'Erasmo L., Borghi C., et al. Association of Hypertriglyceridemia with All-Cause Mortality and Atherosclerotic Cardiovascular Events in a Low-Risk Italian Population: The TG-REAL Retrospective Cohort Analysis. J Am Heart Assoc. 2020;9(19):e015801. https://doi.org/10.1161/JAHA.119.015801

36. Nichols G. A.. Philip S., Reynolds K., Granowitz C.B., Fazio S. Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. J Clin Endocrinol Metab. 2018;103(8):3019-3027. https://doi.org/10.1210/jc.2018-00470

37. Raposeiras-Roubin S., Rosselló X., Oliva B., Fernández-Friera L., Mendiguren J. M., et al. Triglycerides and Residual Atherosclerotic Risk. J Am Coll Cardiol. 2021;77(24):3031-3041. https://doi.org/10.1016/j.jacc.2021.04.059

38. Ginsberg H. N., Packard C. J., Chapman M. J., et al. Triglyceride rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies — a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806. https://doi.org/10.1093/eurheartj/ehab551

39. Nordestgaard B. G. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016; 118(4):547-63. https://doi.org/10.1161/CIRCRESAHA.115.306249.

40. Emerging Risk Factors Collaboration; Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. https://doi.org/10.1001/jama.2009.1619

41. Boren J., Chapman M.J., Krauss R.M., Packard C.J., Bentzon J.F., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330. https://doi.org/10.1093/eurheartj/ehz962

42. Paquette M., Bernard S., Hegele R. A., Baass A. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis. 2019;283:137-142. https://doi.org/10.1016/j.atherosclerosis.2018.12.019

43. O'Dea L. St. L., MacDougall J. , Alexander V. J., Digenio A., Hubbard B., et al. Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. J Endocr Soc. 2019;3(12):2397-2410. https://doi.org/10.1210/js.2019-00214

44. Belhassen M., Van Ganse E., Nolin M., Bérard M., Bada H., et al. 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes. J Clin Endocrinol Metab. 2021;106(3):e1332-e1342. https://doi.org/10.1210/clinem/dgaa838

45. Paquette M., Amyot J., Fantino M., Baass A., Bernard S. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome. J Clin Endocrinol Metab. 2021;106(9):e3473-e3482. https://doi.org/10.1210/clinem/dgab360

46. Patel R. S., Pasea L., Soran H., Downie P., Jones R, et al. Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. Cardiovasc Diabetol. 2022;21(1):102. https://doi.org/10.1186/s12933-022-01525-5

47. Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, D'Erasmo L, Di Costanzo A, Marçais C, Alvarez-Sala Walther LA, Banach M, Borén J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pintó X, Reiner Ž, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018 Aug;275:265-272. https://doi.org/10.1016/j.atherosclerosis.2018.06.814

48. Zhu, Y.; Pan, X.; Zeng, H.; He, W.; Xia, L.; Liu, P.; Zhu, Y.; Chen, Y.; Lv, N. A Study on the Etiology, Severity, and Mortality of 3260 Patients with Acute Pancreatitis According to the Revised Atlanta Classification in Jiangxi, China Over an 8-Year Period. Pancreas. 2017;46(4):504-509. https://doi.org/10.1097/MPA.0000000000000776

49. Hansen S. E. J., Madsen C. M., Varbo A., Nordestgaard B. G. Low Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. Clin Chem. 2019;65(2):321-332. https://doi.org/10.1373/clinchem.2018.294926

50. Scherer J., Singh V. P., Pitchumoni C. S., Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195-203. https://doi.org/10.1097/01.mcg.0000436438.60145.5a

51. Ariza M. J., Rioja J., Ibarretxe D., Camacho A., Díaz-Díaz J. L., et al. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. J Clin Lipidol. 2018;12(6):1482-1492.e3. https://doi.org/10.1016/j.jacl.2018.07.013

52. D'Erasmo L., Di Costanzo A., Cassandra F., Minicocci I., et al. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. Arterioscler Thromb Vasc Biol. 2019;39(12):2531-2541. https://doi.org/10.1161/ATVBAHA.119.313401

53. Gaudet D., Blom D., Bruckert E., Stroes E., Kastelein J., et al. Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results from a Survey of Lipidologist. J Clin Lipidol. 2016;10:680-681. https://doi.org/10.1016/j.jacl.2016.03.048

54. Durgampudi, C.; Noel, P.; Patel, K.; Cline, R.; Trivedi, R.N.; DeLany, J.P.; Yadav, D.; Papachristou, G.I.; Lee, K.; Acharya, C.; et al. Acute lipotoxicity regulates severity of biliary acute pancreatitis without affecting its initiation. Am J Pathol. 2014;184(6):1773-84. https:// doi.org/10.1016/j.ajpath.2014.02.015

55. Kiss L., Fűr G., Pisipati S., et al. Mechanisms linking hypertriglyceridemia to acute pancreatitis. Acta Physiol (Oxf). 2023;237(3):e13916.https://doi.org/10.1111/apha.13916

56. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010 Jun;6(6):335-46. https://doi.org/10.1038/nrendo.2010.50

57. Boot CS, Middling E, Allen J, Neely RDG. Evaluation of the Non HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia. Clin Chem. 2019 Feb;65(2):313-320. https://doi.org/10.1373/clinchem.2018.292425

58. Blokhina AV, Ershova AI, Kiseleva AV, Sotnikova EA, Zharikova AA, Zaicenoka M, Vyatkin YV, Ramensky VE, Kutsenko VA, Shalnova SA, Meshkov AN, Drapkina OM. Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study. Int J Mol Sci. 2023 Aug 24;24(17):13159. https://doi.org/10.3390/ijms241713159

59. Blom DJ, Byrnes P, Jones S, Marais AD. Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. J Lipid Res. 2003 Jan;44(1):212-7. https://doi.org/10.1194/jlr.d200013-jlr200

60. Hegele RA. Illuminating the full spectrum of APOE variation. Atherosclerosis. 2023 Nov;385:117311. https://doi.org/10.1016/j.atherosclerosis.2023.117311

61. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43(6):891-915. PMID: 4930042 PMCID: PMC2427808.

62. Koopal C, Marais AD, Visseren FL. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Curr Opin Endocrinol Diabetes Obes. 2017 Apr;24(2):133-139. https://doi.org/10.1097/MED.0000000000000316

63. Bashir B, Kwok S, Wierzbicki AS, Jones A, Dawson C, Downie P, Jenkinson F, Delaney H, Mansfield M, Datta D, Teoh Y, Hamilton P, Forrester N, O'Sullivan D, Ferdousi M, Durrington PN, AbdelRazik A, Gallo A, Moulin P, Soran H. Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS). Atherosclerosis. 2024 Apr;391:117476. https://doi.org/10.1016/j.atherosclerosis.2024.117476

64. Alves M., Laranjeira F., Correia-da-Silva G. Understanding Hypertriglyceridemia: Integrating Genetic Insights. Genes (Basel). 2024;15(2):190. https://doi.org/10.3390/genes15020190

65. Dron J.S., Hegele R.A. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455. https://doi.org/10.3389/fendo.2020.00455

66. Драпкина О.М., Лимонова А.С., Гарбузова Е.В., Мешков А.Н., Ершова А.И. Персонализированная профилактика: возможности и ограничения оценки полигенного риска. Российский журнал персонализированной медицины. 2023;3(5):14-21. EDN: AWYDDG. https://doi.org/10.18705/2782-3806-2023-3-5-14-21 [Drapkina O.M., Limonova A.S., Garbuzova E.V., Meshkov A.N., Ershova A.I. Personalized prevention: possibilities and limitations of polygenic risk assessment. Russian Journal for Personalized Medicine. 2023;3(5):14-21. (In Russ.). EDN: AWYDDG. https://doi.org/10.18705/2782-3806-2023-3-5-14-21]

67. Guay SP, Paquette M, Taschereau A, Girard L, Desgagné V, Bouchard L, Bernard S, Baass A. Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia. Atherosclerosis. 2024 May;392:117489. https://doi.org/10.1016/j.atherosclerosis.2024.117489

68. Kirkpatrick CF, Sikand G, Petersen KS, Anderson CAM, Aspry KE, Bolick JP, Kris-Etherton PM, Maki KC. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. J Clin Lipidol. 2023 Jul-Aug;17(4):428-451. https://doi.org/10.1016/j.jacl.2023.05.099

69. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. https://doi.org/10.1056/NEJMoa1001282

70. Kim KS, Hong S, Han K, Park CY. Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. Metabolism. 2022;137:155327. https://doi.org/10.1016/j.metabol.2022.15532

71. Kim NH, Han KH, Choi J, et al, Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019;366:l5125. https://doi.org/10.1136/bmj.l5125

72. Hong S, Kim KS, Han K, Park CY. Fenofibrate's impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study. Cardiovasc Diabetol. 2024;23(1):263. https://doi.org/10.1186/s12933-024-02353-5

73. Kim NH, Kim JY, Choi J, Kim SG. Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):118-127. https://doi.org/10.1093/ehjcvp/pvad090

74. Ferreira JP, Vasques-Nóvoa F, Ferrão D, Saraiva F, Falcão-Pires I, Neves JS, Sharma A, Rossignol P, Zannad F, Leite-Moreira A. Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. Diabetes Care. 2022 Jul 7;45(7):1584-1591. https://doi.org/10.2337/dc21-1977

75. Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 Oct 15;140(16):1308-1317. https://doi.org/10.1161/CIRCULATIONAHA.119.041998

76. Irfan A, Haider SH, Nasir A, et al. Assessing the Efficacy of Omega-3 Fatty Acids + Statins vs. Statins Only on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of 40,991 Patients. Curr Probl Cardiol. 2024;49(2):102245. https://doi.org/10.1016/j.cpcardiol.2023.102245

77. Luo S, Hou H, Wang Y, Li Y, Zhang L, Zhang H, Jin Q, Wu G, Wang X. Effects of omega-3, omega-6, and total dietary polyunsaturated fatty acid supplementation in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Food Funct. 2024 Feb 5;15(3):1208-1222. https://doi.org/10.1039/d3fo02522e

78. Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol. 2009 Sep;54(3):196-203. https://doi.org/10.1097/FJC.0b013e3181b0cf71

79. Stroes ESG, Susekov AV, de Bruin TWA, Kvarnström M, Yang H, Davidson MH. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018 Mar-Apr;12(2):321-330. https://doi.org/10.1016/j.jacl.2017.10.012

80. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019 Sep 17;140(12):e673-e691. https://doi.org/10.1161/CIR.0000000000000709

81. Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015 Jun;11(6):352-62. https://doi.org/10.1038/nrendo.2015.26

82. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020 Apr;287(4):340-348. https://doi.org/10.1111/joim.13016

83. Das Pradhan A, Glynn RJ, Fruchart JC, et al; PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923-1934. https://doi.org/10.1056/NEJMoa2210645

84. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. https://doi.org/10.1093/eurheartj/ehx144

85. Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397-405. https://doi.org/10.1016/S0140-6736(14)61368-4

86. Grupp C, Beckermann J, Köster E, Zewinger S, Knittel M, Walek T, Hohenstein B, Jaeger B, Spitthöver R, Klingel R, Fassbender CM, Tyczynski B. Relapsing and Progressive Complications of Severe Hypertriglyceridemia: Effective Long-Term Treatment with Double Filtration Plasmapheresis. Blood Purif. 2020;49(4):457-467. https://doi.org/10.1159/000506506

87. Saleh MA, Mansoor E, Cooper GS. Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy. World J Gastroenterol. 2017;23(40):7332-7336. https://doi.org/10.3748/wjg.v23.i40.7332

88. Stefanutti C, Di Giacomo S, Vivenzio A, Labbadia G, Mazza F, D’Alessandri G, Russi G, De Silvestro G, Marson P. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif Organs. 2009;33(12):1096-1102. https://doi.org/10.1111/j.1525-1594.2009.00810.x

89. Schaap-Fogler M, Schurr D, Schaap T, Leitersdorf E, Rund D. Long term plasma exchange for severe refractory hypertriglyceridemia: a decade of experience demonstrates safety and efficacy. J Clin Apher. 2009;24(6):254-8. https://doi.org/10.1002/jca.20224

90. Thomas PE, Vedel-Krogh, Nielsen SF, Nordestgaard, Kamstrup PR, et al. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events. Journal of the American College Cardiology 2023;82:2265-2276; https://doi.org/10.1016/j.jacc.2023.10.009

91. Langstedt A, Nordestgaard B, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. Journal of the American College Cardiology 2019;74(1):54-66. https://doi.org/10.1016/j.jacc.2019.03.524

92. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM et al. Unmet Needs in Understanding Lipoprotein(a) Pathophysiology: NHLBI Working Group Recommendations to Reduce Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College Cardiology 2018;71(2):177-192. https:// doi.org/10.1016/j.jacc.2017.11.014

93. Björnson E, Adiels M, Taskinen MR, Stephen Burgess S , John Chapman MJ, Chris J. Packard et al. Journal of the American College Cardiology 2024;83(3):385-395. https://doi.org/10.1016/j.jacc.2023.10.039

94. Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Hudgins LC, Kayikcioglu M, Masana L, Parhofer KG, Roeters van Lennep JE, Santos RD, Stroes ESG, Watts GF, Wiegman A, Stock JK, Tokgözoğlu LS, Catapano AL, Ray KK. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 1;44(25):2277-2291. https://doi.org/10.1093/eurheartj/ehad197

95. Abe T., Matsudo H., Abe R., Abe S., Asada H., Ashida A., Baba A., Eguchi K., Eguchi Y., Endo Y., Fujimori Y., Furuichi K. et al. The Japanese Society for Apheresis clinical practice guideline foe therapeutic apheresis Thet Apher Dial. 2021;25:728-876. https://doi.org/10.1111/1744-9987.13749

96. Connelly-Smith L., Alquist C.R., Aqui N., Hofmann J.C., Klingel R., Onwuemene O.A.,Patriquin C.J., Pham H.P., Sanchez A.P., Schneiderman J., Witt V, Zantek N.D., Dunbar N.M. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38:77-278. HTTPS://DOI.ORG/10.1002/jca.22043

97. Ezhov M.V., Il'ina L.N., Safarova M.S., Afanasieva O.I., Adamova I.Y., Atanesyan R.V., Konovalov G.A., Akchurin R.S., Pokrovsky S.N. Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins. Atheroscler. Suppl. 2013;14(1):101-105. http://dx.doi.org/10.1016/j.atherosclerosissup.2012.10.014

98. Kitano Y., Thompson G.R. The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone. Ther. Apher. 1997 May;1(2):187-90. https://doi.org/10.1111/j.1744-9987.1997.tb00039.x

99. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., Stalenhoef A.F. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996 May 15;93(10):1826-1835. https://doi.org/10.1161/01.cir.93.10.1826

100. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 1998 Dec 15;82(12):1489-1495. https://doi.org/10.1016/s0002-9149(98)00692-4

101. Matsuzaki M., Hiramori K., Imaizumi T., Kitabatake A., Hishida H., Nomura M., Fujii T., Sakuma I., Fukami K., Honda T., Ogawa H., Yamagishi M. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J. Am. Coll. Cardiol. 2002 Jul 17;40(2):220-227. https://doi.org/10.1016/s0735-1097(02)01955-1

102. Nishimura S., Sekiguchi M., Kano T., Ishiwata S., Nagasaki F., Nishide T., Okimoto T., Kutsumi Y., Kuwabara Y., Takatsu F., Nishikawa H., Daida H., Yamaguchi H. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999 Jun;144(2):409-417. https://doi.org/10.1016/s0021-9150(98)00328-1

103. Heigl F., Hettich R., Lotz N., Reeg H., Pflederer T., Osterkorn D., et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler. Suppl. 2015 May:18:154-162. https://doi.org/10.1016/j.atherosclerosissup.2015.02.013

104. Khan T.Z., Hsu L.Y., Arai A.E., Rhodes S., Pottle A., Wage R., et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a):a randomized controlled cross-over trial. Eur. Heart. J. 2017;38(20):1561-1569. https://doi.org/10.1093/eurheartj/ehx178

105. Klingel R., Heibges A., Fassbender C., ProLiFe-Study G. Prevention of cardiovascular complications in patients with Lp(a) hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Clin. Res. Cardiol. Suppl. 2017 Mar;12(Suppl 1):38-43. https://doi.org/10.1007/s11789-017-0082-3

106. Pokrovsky S.N., Afanasieva O.I., Safarova M.S., Balakhonova T.V., Matchin Yu.G., Adamova I.Yu., Konovalov G.A., Ezhov M.V. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity. Atheroscler. Suppl. 2017 Nov:30:166-173. https://doi.org/10.1016/j.atherosclerosissup.2017.05.004

107. Safarova M.S., Ezhov M.V., Afanasieva O.I., Matchin Yu.G., Atanesyan R.V., Adamova I.Yu., Utkina E.A., Konovalov G.A., Pokrovsky S.N. Effect of specific Lp(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 2013 Jan;14(1):93-99. https://doi.org/10.1016/j.atherosclerosissup.2012.10.015

108. Schatz U., Tselmin S., Muller G., Julius U., Hohenstein B., Fischer S., et al. Most significant reduction of cardiovascular events in patients undergoing lipoprotein apheresis due to raised Lp(a) levels – A multicenter observational study. Atheroscler. Suppl. 2017 Nov:30:246-252. https://doi.org/10.1016/j.atherosclerosissup.2017.05.047

109. Grupp C, Beckermann J, Köster E, Zewinger S, Knittel M, Walek T, Hohenstein B, Jaeger B, Spitthöver R, Klingel R, Fassbender CM, Tyczynski B. Relapsing and Progressive Complications of Severe Hypertriglyceridemia: Effective Long-Term Treatment with Double Filtration Plasmapheresis. Blood Purif. 2020;49(4):457-467. https://doi.org/10.1159/000506506

110. Saleh MA, Mansoor E, Cooper GS. Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy. World J Gastroenterol. 2017;23(40):7332-7336. https://doi.org/10.3748/wjg.v23.i40.7332

111. Stefanutti C, Di Giacomo S, Vivenzio A, Labbadia G, Mazza F, D’Alessandri G, Russi G, De Silvestro G, Marson P. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif Organs. 2009;33(12):1096-1102. https://doi.org/10.1111/j.1525-1594.2009.00810.x

112. Schaap-Fogler M, Schurr D, Schaap T, Leitersdorf E, Rund D. Long-term plasma exchange for severe refractory hypertriglyceridemia: a decade of experience demonstrates safety and efficacy. J Clin Apher. 2009;24(6):254-8. https://doi.org/10.1002/jca.20224

113. Zhang XL, Li F, Zhen YM, Li A, Fang Y. Clinical Study of 224 Patients with Hypertriglyceridemia Pancreatitis. Chin Med J (Engl). 2015;128(15):2045-9. https://doi.org/10.4103/0366-6999.161361

114. Anedda S., Mura S., Marcello C., Pintus P. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women. Transfus. Apher. Sci. 2011 Feb;44(1):21-24. https://doi.org/10.1016/j.transci.2010.12.004

115. Cashin-Hemphill L., Noone M., Abbott J.F., Waksmonski C.A., Lees R.S. Low-density lipoprotein apheresis therapy during pregnancy. Am. J. Cardiol. 2000 Nov 15;86(10):1160, A10. https://doi.org/10.1016/s0002-9149(00)01183-8

116. Ertorer M.E., Guvenc B., Haydardedeoglu B., Tekinturhan F. A case report of the cascade filtration system: a safe and effective method for low-density lipoprotein apheresis during pregnancy. Ther. Apher Dial. – 2008. – Vol.12, №5. – P. 396-400.

117. Defesche JC, Gidding SS, Harada-Shiba M, et al. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 7;3:17093. https://doi.org/10.1038/nrdp.2017.93

118. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-3490a. https://doi.org/10.1093/eurheartj/eht273

119. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520-1530. Epub 2020 Mar 18. PMID: 32197277. https://doi.org/10.1056/NEJMoa1913805

120. Santos RD, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, Scemama M, Manvelian G, Garon G, Daniels S. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA Pediatr. 2024 Mar 1;178(3):283-293. PMID: 38315470; PMCID: PMC10845038. https://doi.org/10.1001/jamapediatrics.2023.6477

121. Shuja D, Mian MU, Kaur Dhanjal M, Mengar J, Butt AA, Chaudhari SS, Wei CR, Khan A. Comparison of Efficacy of Atorvastatin and Rosuvastatin in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Cureus. 2024 Sep 4;16(9):e68602. https://doi.org/10.7759/cureus.68602

122. Yu S, Jin J, Chen Z, Luo X. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020 Aug 23;19(1):194. https://doi.org/10.1186/s12944-020-01369-6

123. de Oliveira Almeida G, Balieiro C, Bertoli ED, Moreira MEL, Silva ALS, Minucci BS, Zapparoli I, Maluf MS, Carvalho HCP, Dos Santos Borges R, Pasqualotto E, Nienkötter T, Alves V, Guida CM. Cardiovascular benefits of statin plus ezetimibe combination therapy versus statin monotherapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Coron Artery Dis. 2025 Jan 1;36(1):9-17. https://doi.org/10.1097/MCA.0000000000001407

124. Yifan D, Yue M, Yubin Z, Jiapei G, Xun S, Shenghu H, Li Z, Jing Z. The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis. Int J Cardiol. 2024 Mar 15;399:131775. https://doi.org/10.1016/j.ijcard.2024.131775

125. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, Gorny B, Wirianta J, Kubica J, Kelm M, de Boer MJ, Suryapranata H. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014 May 15;113(10):1753-64. https://doi.org/10.1016/j.amjcard.2014.02.034

126. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007 Dec 1;370(9602):1829-39. https://doi.org/10.1016/S0140-6736(07)61778-4

127. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MS. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 Nov 21;396(10263):1637-1643. https://doi.org/10.1016/S0140-6736(20)32332-1

128. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020 Nov 21;396(10263):1644-1652. https://doi.org/10.1016/S0140-6736(20)32233-9

129. Reiner Ž. Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Curr Atheroscler Rep. 2014. 16(7). https://doi.org/10.1007/s11883-014-0420-6

130. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192. https://doi.org/10.1016/S0140-6736(11)60739-3

131. Сonelli M., Wanner C. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med. 2014;160(3):182-189. https://doi.org/10.7326/m13-2453

132. Debette S, Metso T, Pezzini A, Abboud S, Metso A, Leys D, Bersano A, Louillet F, Caso V, Lamy C, Medeiros E, Samson Y, Grond-Ginsbach C, Engelter ST, Thijs V, Beretta S, Béjot Y, Sessa M, Lorenza Muiesan M, Amouyel P, Castellano M, Arveiler D, Tatlisumak T, Dallongeville J; Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) Group. Association of vascular risk factors with cervical artery dissection and ischemic stroke in young adults. Circulation. 2011 Apr 12;123(14):1537-44. https:// doi.org/10.1161/CIRCULATIONAHA.110.000125

133. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484

134. Sung EM, Saver JL. Statin Overuse in Cerebral Ischemia Without Indications: Systematic Review and Annual US Burden of Adverse Events. Stroke. 2024 Aug;55(8):2022-2033. https://doi.org/10.1161/STROKEAHA.123.044071

135. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavallée PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touzé E, Varenne O, Vicaut É, Yelles N, Bruckert E; Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020 Jan 2;382(1):9. https://doi.org/10.1056/NEJMoa1910355

136. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. Epub 2017 Mar 17. PMID: 28304224. https://doi.org/10.1056/NEJMoa1615664

137. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. Epub 2018 Nov 7. PMID: 30403574. https://doi.org/10.1056/NEJMoa1801174

138. Lee M, Cheng C, Wu Y, Lee J, Hsu C, Ovbiagele B. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA Neurol. 2022;79(4):349-358. https://doi.org/10.1001/jamaneurol.2021.5578

139. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. https://doi.org/10.1056/NEJMoa061894. Erratum in: N Engl J Med. 2018 Jun 13;378(25):2450. PMID: 16899775. https://doi.org/10.1056/NEJMx180019

140. Bétrisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, Blum MR, Aujesky D, Rodondi N, Gencer B. Lipid Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2024 Feb 20;13(4):e030714. Epub 2024 Feb 7. PMID: 38323514; PMCID: PMC11010101. https://doi.org/10.1161/JAHA.123.030714

141. Agarwal A, Prasad GV. Post-transplant dyslipidemia: mechanisms, diagnosis and management. World J Transplant 2016;6:125-134. https://doi.org/10.5500/wjt.v6.i1.125

142. Bamgbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Ther Adv Endocrinol Metab 2016;7:110-127. https://doi.org/10.1177/2042018816641580

143. Opałka B, Żołnierczuk M, Grabowska M. Immunosuppressive Agents-Effects on the Cardiovascular System and Selected Metabolic Aspects: A Review. J Clin Med. 2023 Nov 5;12(21):6935. https://doi.org/10.3390/jcm12216935

144. Pober J.S., Chih S., Kobashigawa J., Madsen J.C., Tellides G. Cardiac allograft vasculopathy: current review and future research directions. Cardiovasc Res. 2021 Nov 22;117(13):2624–2638. https://doi.org/10.1093/cvr/cvab259

145. Page RL II, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation. 2005;111:230-239. https://doi.org/10.1161/01.cir.0000151805.86933.35

146. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl. 2009;15:504-508. https://doi.org/10.1002/lt.21710

147. Shaw SM, Chaggar P, Ritchie J, Shah MK, Baynes AC, O’Neill N, Fildes JE, Yonan N, Williams SG. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation. 2009;87:771-775. https://doi.org/10.1097/tp.0b013e318198d7d0

148. Warden BA, Kaufman T, Minnier J, Duell PB, Fazio S, Shapiro MD. Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients. JACC Case Rep. 2020 Feb 12;2(3):396-399. https://doi.org/10.1016/j.jaccas.2019.09.026

149. Sammour Y, Dezorzi C, Austin BA, Borkon AM, Everley MP, Fendler TJ, Khumri TM, Lawhorn SL, Nassif ME, Vodnala D, Magalski A, Kao AC, Sperry BW. PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail. 2021 Jul;27(7):812-815. https://doi.org/10.1016/j.cardfail.2021.02.018

150. Симоненко М.А., Алиева А.С., Ситникова М.Ю., Федотов П.А. Первый опыт в Российской Федерации лечения дислипидемии препаратами миРНК у пациентов после трансплантации сердца. Российский кардиологический журнал. 2024;29(1):5747. EDN: ISMANC. https://doi.org/10.15829/1560-4071-2024-5747 [Simonenko M.A., Alieva A.S., Sitnikova M.Yu., Fedotov P.A. First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation. Russian Journal of Cardiology. 2024;29(1):5747. (In Russ.). EDN: ISMANC. https://doi.org/10.15829/1560-4071-2024-5747]

151. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019 Jul 9;140(2):e98-e124. https://doi.org/10.1161/CIR.0000000000000695

152. Li Y, Wang Z, Xia H, Zhang J. Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis. Front Med (Lausanne). 2021 Nov 8;8:769-740. https://doi.org/10.3389/fmed.2021.769740

153. Li Y, Wang Z, Xia H, Zhang J. Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis. Front Med (Lausanne). 2021 Nov 8;8:769-740. https://doi.org/10.3389/fmed.2021.769740

154. Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, Foldyna B, Looby SE, Desvigne-Nickens P, Alston-Smith B, Leon Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023 Aug 24;389(8):687-699. https://doi.org/10.1056/NEJMoa2304146

155. Nirmala N, Avendano EE, Morin RA. Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis. Infect Dis (Lond). 2022 Feb;54(2):99-109. https://doi.org/10.1080/23744235.2021.1982140

156. Boccara F, Caramelli B, Calmy A, Kumar P, López JAG, Bray S, Cyrille M, Rosenson RS; investigators of the BEIJERINCK study. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. AIDS. 2022 Apr 1;36(5):675-682. https://doi.org/10.1097/QAD.0000000000003175

157. Xiao Y, Ba Z, Pang S, Liu D, Wang H, Liang H, Wang Y, Yuan J. PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin Limited Conditions? Rev Cardiovasc Med. 2022 Nov 9;23(11):380. https://doi.org/10.31083/j.rcm2311380

158. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection. 2002;30(1):26-31. https://doi.org/10.1007/s15010-001-2052-3

159. Palacios R, Santos J, González M, et al. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(2):251-253. https://doi.org/10.1097/00126334-200210010-00018

160. Grandi AM, Nicolini E, Rizzi L, Caputo S, Annoni F, Cremona AM, Marchesi C, Guasti L, Maresca AM, Grossi P. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. J Int AIDS Soc. 2014 Aug 21;17(1):19004. https://doi.org/10.7448/IAS.17.1.19004

161. Ежов М. В., Кухарчук В. В., Сергиенко И. В., Алиева А. С., Анциферов М. Б., Аншелес А. А., Арабидзе Г. Г., Аронов Д. М., Арутюнов Г. П., Ахмеджанов Н. М., Балахонова Т. В., Барбараш О. Л., Бойцов С. А., Бубнова М. Г., Воевода М. И., Галстян Г. Р., Галявич А. С., Горнякова Н. Б., Гуревич В. С., Дедов И. И., Драпкина О. М., Дупляков Д. В., Ерегин С. Я., Ершова А. И., Иртюга О. Б., Карпов Р. С., Карпов Ю. А., Качковский М. А., Кобалава Ж. Д., Козиолова Н. А., Коновалов Г. А., Константинов В. О., Космачева Е. Д., Котовская Ю. В., Мартынов А. И., Мешков А. Н., Небиеридзе Д. В., Недогода С. В., Обрезан А. Г., Олейников В. Э., Покровский С. Н., Рагино Ю. И., Ротарь О. П., Скибицкий В. В., Смоленская О. Г., Соколов А. А., Сумароков А. Б., Ткачева О. Н., Филиппов А. Е., Халимов Ю. Ш., Чазова И. Е., Шапошник И. И., Шестакова М. В., Якушин С. С., Шляхто Е. В. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. EDN YVZOWJ. https://doi.org/10.15829/1560-4071-2023-5471 [Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A., Arabidze G.G., Aronov D.M., Arutyunov G.P., Akhmedzhanov N.M., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galstyan G.R., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Dedov I.I., Drapkina O.M., Duplyakov D.V., Eregin S.Ya., Ershova A.I., Irtyuga O.B., Karpov R.S., Karpov Yu.A., Kachkovsky M.A., Kobalava Zh.D., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Kotovskaya Yu.V., Martynov A.I., Meshkov A.N., Nebieridze D.V., Nedogoda S.V., Obrezan A.G., Oleinikov V.E., Pokrovsky S.N., Ragino Yu.I., Rotar O.P., Skibitsky V.V., Smolenskaya O.G., Sokolov A.A., Sumarokov A.B., Filippov E., Halimov Yu.Sh., Chazova I.E., Shaposhnik I.I., Shestakova M.V., Yakushin S.S., Shlyakhto E.V. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5471]